270 related articles for article (PubMed ID: 26600976)
1. Lymphoproliferative disorders in inflammatory bowel disease patients on immunosuppression: Lessons from other inflammatory disorders.
Lam GY; Halloran BP; Peters AC; Fedorak RN
World J Gastrointest Pathophysiol; 2015 Nov; 6(4):181-92. PubMed ID: 26600976
[TBL] [Abstract][Full Text] [Related]
2. Posttransplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus infection and immunosuppression.
Newell KA; Alonso EM; Whitington PF; Bruce DS; Millis JM; Piper JB; Woodle ES; Kelly SM; Koeppen H; Hart J; Rubin CM; Thistlethwaite JR
Transplantation; 1996 Aug; 62(3):370-5. PubMed ID: 8779685
[TBL] [Abstract][Full Text] [Related]
3. Epstein-Barr virus in inflammatory bowel disease: the spectrum of intestinal lymphoproliferative disorders.
Nissen LH; Nagtegaal ID; de Jong DJ; Kievit W; Derikx LA; Groenen PJ; van Krieken JH; Hoentjen F
J Crohns Colitis; 2015 May; 9(5):398-403. PubMed ID: 25740811
[TBL] [Abstract][Full Text] [Related]
4. Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation.
Taylor AL; Marcus R; Bradley JA
Crit Rev Oncol Hematol; 2005 Oct; 56(1):155-67. PubMed ID: 15979320
[TBL] [Abstract][Full Text] [Related]
5. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.
Schubert S; Renner C; Hammer M; Abdul-Khaliq H; Lehmkuhl HB; Berger F; Hetzer R; Reinke P
J Heart Lung Transplant; 2008 Jan; 27(1):100-5. PubMed ID: 18187094
[TBL] [Abstract][Full Text] [Related]
6. Epstein-Barr virus-related disorders in children undergoing renal transplantation with tacrolimus-based immunosuppression.
Ellis D; Jaffe R; Green M; Janosky JJ; Lombardozzi-Lane S; Shapiro R; Scantlebury V; Vivas C; Jordan ML
Transplantation; 1999 Oct; 68(7):997-1003. PubMed ID: 10532541
[TBL] [Abstract][Full Text] [Related]
7. Surveillance of Epstein-Barr virus infection as a risk factor for post-transplant lymphoproliferative disorder in pediatric renal transplant recipients.
Köpf S; Tönshoff B
Pediatr Nephrol; 2004 Apr; 19(4):365-8. PubMed ID: 14963763
[TBL] [Abstract][Full Text] [Related]
8. Low-dose immunosuppression reduces the incidence of post-transplant lymphoproliferative disease in pediatric liver graft recipients.
Ganschow R; Schulz T; Meyer T; Broering DC; Burdelski M
J Pediatr Gastroenterol Nutr; 2004 Feb; 38(2):198-203. PubMed ID: 14734884
[TBL] [Abstract][Full Text] [Related]
9. Systemic Epstein-Barr Virus-Positive T/NK Lymphoproliferative Diseases With
Ishimura M; Eguchi K; Shiraishi A; Sonoda M; Azuma Y; Yamamoto H; Imadome KI; Ohga S
Front Pediatr; 2019; 7():183. PubMed ID: 31231620
[TBL] [Abstract][Full Text] [Related]
10. Inflammatory bowel disease and lymphoproliferative disorders: the dust is starting to settle.
Sokol H; Beaugerie L
Gut; 2009 Oct; 58(10):1427-36. PubMed ID: 19749141
[TBL] [Abstract][Full Text] [Related]
11. Primary Epstein-Barr virus infection, seroconversion, and post-transplant lymphoproliferative disorder in seronegative renal allograft recipients: a prospective cohort study.
Hosseini-Moghaddam SM; Alhomayeed B; Soliman N; Weir MA; House AA
Transpl Infect Dis; 2016 Jun; 18(3):423-30. PubMed ID: 27016725
[TBL] [Abstract][Full Text] [Related]
12. Determination of risk factors for Epstein-Barr virus-associated posttransplant lymphoproliferative disorder in pediatric liver transplant recipients using objective case ascertainment.
Guthery SL; Heubi JE; Bucuvalas JC; Gross TG; Ryckman FC; Alonso MH; Balistreri WF; Hornung RW
Transplantation; 2003 Apr; 75(7):987-93. PubMed ID: 12698085
[TBL] [Abstract][Full Text] [Related]
13. Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorders with a T- or NK-cell phenotype.
Satou A; Tsuzuki T; Nakamura S
J Clin Exp Hematop; 2019; 59(2):56-63. PubMed ID: 31257346
[TBL] [Abstract][Full Text] [Related]
14. Two rare cases of Epstein-Barr virus-associated lymphoproliferative disorders in inflammatory bowel disease patients on thiopurines and other immunosuppressive medications.
Subramaniam K; Cherian M; Jain S; Latimer M; Corbett M; D'Rozario J; Pavli P
Intern Med J; 2013 Dec; 43(12):1339-42. PubMed ID: 24330365
[TBL] [Abstract][Full Text] [Related]
15. Ratio between Epstein-Barr viral load and anti-Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease.
Smets F; Latinne D; Bazin H; Reding R; Otte JB; Buts JP; Sokal EM
Transplantation; 2002 May; 73(10):1603-10. PubMed ID: 12042647
[TBL] [Abstract][Full Text] [Related]
16. Immunosuppression for inflammatory bowel disease does not influence Epstein-Barr viral load in the short-term.
Rodríguez-Lago I; Merino O; López de Goicoechea MJ; Aranzamendi M; Zubiaurre L; Muro N; Ortiz de Zárate J; Cilla G; Cabriada JL
Gastroenterol Hepatol; 2019 Nov; 42(9):542-547. PubMed ID: 31402179
[TBL] [Abstract][Full Text] [Related]
17. EBV Status and Thiopurine Use in Pediatric IBD.
Gordon J; Ramaswami A; Beuttler M; Jossen J; Pittman N; Lai J; Dunkin D; Benkov K; Dubinsky M
J Pediatr Gastroenterol Nutr; 2016 May; 62(5):711-4. PubMed ID: 26655944
[TBL] [Abstract][Full Text] [Related]
18. The Immune Response to Epstein Barr Virus and Implications for Posttransplant Lymphoproliferative Disorder.
Martinez OM; Krams SM
Transplantation; 2017 Sep; 101(9):2009-2016. PubMed ID: 28376031
[TBL] [Abstract][Full Text] [Related]
19. Biological Difference Between Epstein-Barr Virus Positive and Negative Post-transplant Lymphoproliferative Disorders and Their Clinical Impact.
Ferla V; Rossi FG; Goldaniga MC; Baldini L
Front Oncol; 2020; 10():506. PubMed ID: 32457824
[TBL] [Abstract][Full Text] [Related]
20. The Epstein-Barr virus and post-transplant lymphoproliferative disease: interplay of immunosuppression, EBV, and the immune system in disease pathogenesis.
Tanner JE; Alfieri C
Transpl Infect Dis; 2001 Jun; 3(2):60-9. PubMed ID: 11395971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
